Heart Rate on a GLP-1: Why the Average Hides the Number That Matters

Two true statements

These drugs raise resting heart rate by an average of 1 to 4 beats per minute.

About a quarter of adults taking one had a resting heart rate 20 or more beats per minute above their own baseline at some visit.

Both come from the same section of the same label¹. The first is the one that gets quoted, and it is why the subject is usually waved away. The second is the one that describes what people actually feel.

The distribution, not the average

Wegovy's label sets out maximum change from baseline at any study visit, against placebo¹.

Zepbound's figure is similar in shape: a mean increase of 1 to 3 bpm, against no increase in the placebo group².

Look at the gap between the last row and the one above it. An average of a few beats per minute is arithmetically compatible with a quarter of people having a 20-beat jump at some point, because most people sit near zero and a minority move a lot. If you are in that minority, being told the average is 1–4 bpm does not describe your experience — and it is not a reason to think you are imagining it.

The placebo column is doing useful work here too. Sixteen percent of people on placebo also recorded a 20+ bpm maximum at some visit¹. Resting heart rate is variable, measurement is imperfect, and not every jump is the drug. The drug roughly adds ten percentage points on top of that.

The sentence almost nobody quotes

The same section carries three instructions, and the third is the one worth carrying into an appointment¹:

• Monitor heart rate at regular intervals, consistent with usual clinical practice.
• Instruct patients to tell their healthcare provider about palpitations or a racing heartbeat while at rest.
• "If patients experience a sustained increase in resting heart rate, discontinue WEGOVY."

That third line is a discontinuation instruction, printed in the label. Not "consider," not "review" — discontinue. It is conditional on a sustained increase rather than a bad afternoon, and judging that is your prescriber's job. But if you have been told that a persistently faster resting pulse is just something to live with, that is not what the document says.

It also means "report palpitations at rest" is an instruction someone was supposed to give you. Most people never hear it, and then interpret their own symptom as anxiety.

Why mothers in particular get told it is anxiety

There is a well-documented pattern of women's cardiac symptoms being attributed to stress before they are investigated, and a tired mother reporting a racing heart while sitting still is close to the center of it.

Two things make the confusion genuine rather than lazy. Anxiety and a raised resting heart rate feel similar from the inside. And the other common causes on this drug are real: dehydration from vomiting or diarrhea raises heart rate, and so does under-eating. Those are worth fixing regardless.

The distinguishing question is not how it feels but when it happens. At rest is the word the label uses¹. A pulse that climbs when you are sitting still, repeatedly, over weeks, is a different observation from feeling wired after a hard day.

The adolescent number, if it applies to you

If you have a child on one of these, the same section reports a separate figure: in a trial of patients aged 12 and over with normal baseline heart rate, 54% on Wegovy had a maximum increase of 20 bpm or more, against 39% on placebo¹. That is a substantially higher proportion than the adult figure, in a group with normal starting heart rates.

Where this sits on the evidence scale

This is label-grade data from randomized placebo-controlled trials, with the comparison arm printed alongside — about as solid as safety information gets, and the monitoring and discontinuation instructions are regulatory text rather than anyone's interpretation.

What the data does not establish is what a raised resting heart rate over years does to you. The trials measured heart rate as a safety signal, not a long-term outcome, and the label offers no threshold at which a rise becomes dangerous. "Sustained" is left to clinical judgment. So the honest position is that the short-term effect is well quantified, the instruction for what to do about it is explicit, and the long-run significance in an otherwise healthy woman has not been studied.